Your browser doesn't support javascript.
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery.
Gerhardt, Alana; Voigt, Emily; Archer, Michelle; Reed, Sierra; Larson, Elise; Van Hoeven, Neal; Kramer, Ryan; Fox, Christopher; Casper, Corey.
  • Gerhardt A; Product Development Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Voigt E; RNA Vaccines Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Archer M; Product Development Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Reed S; Product Development Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Larson E; Formulation Sciences Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Van Hoeven N; RNA Vaccines Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Kramer R; Product Development Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Fox C; Formulation Sciences Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Casper C; Product Development Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.
Mol Ther Methods Clin Dev ; 25: 205-214, 2022 Jun 09.
Article in English | MEDLINE | ID: covidwho-1740073
ABSTRACT
Current RNA vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at -20°C or -70°C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) delivery system for RNA vaccines that has the potential to address these concerns. Liquid NLC alone is stable at refrigerated temperatures for ≥1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for ≥8 months or refrigerated temperature for ≥21 months while still retaining the ability to express protein in vivo. The thermostability of this NLC/RNA vaccine delivery platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mol Ther Methods Clin Dev Year: 2022 Document Type: Article Affiliation country: J.omtm.2022.03.009

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mol Ther Methods Clin Dev Year: 2022 Document Type: Article Affiliation country: J.omtm.2022.03.009